Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials, Accelerating Study Design and Execution
New offerings combine a variety of Medidata technologies and learnings from thousands of previous trials to streamline study management for Phase II and Phase III studies in specified therapeutic areas, reinforcing FDA guidance for patient-centered study design and execution
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has introduced two new bundled offerings to meet the growing demands of oncology and vaccine research. Medidata Oncology Solutions and Medidata Vaccine Solutions reinforce the FDA guidance for patient-centered endpoints, adaptive trial designs, and trial diversity. By unifying key trial components such as real-time patient-reported outcomes and imaging management, these bundled solutions will aid sponsors by reducing trial complexity, accelerating decision-making, and improving assessments of treatment efficacy and safety.
"Oncology and vaccine trials face significant challenges in recruiting diverse patients, ensuring rapid execution, and maintaining and monitoring patient safety," said Joseph Schmidt, chief operating officer, Medidata. "By making these new bundled capabilities readily available to customers, we can deliver a solution built on Medidata’s vast experience and expertise in these two important therapeutic areas. These bundles are designed to help customers navigate the complicated stages of these studies while advancing life-saving treatments."
Medidata, with more than 25 years of oncology and vaccine experience and the largest global trial datasets, has conducted approximately 9,000 oncology studies and 750 trials in vaccines. In 2023, it was recorded that 93% of oncology drug approvals went through Medidata. The company was also on the frontlines of COVID-19, supporting hundreds of trials, including the development of one of the most effective mRNA vaccines used to fight the virus.
Both solutions deliver a unified data ecosystem by integrating Medidata Rave EDC, Medidata eCOA, Medidata Rave Imaging, Medidata Clinical Data Studio, and Health Record Connect. For more information about Medidata’s new oncology and vaccine solution bundles, visit our therapeutics landing page.
About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 34,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across approximately 2,200 customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.
About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all – consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com
© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031324962/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Elevates Pamela Hennard to Chief Diversity and Inclusion Officer, Accelerating its Vision for a More Inclusive Future31.10.2024 17:00:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Pamela Hennard as the new Chief Diversity and Inclusion Officer. In her expanded role, Pamela will lead NetApp's efforts to foster diversity, equity, and inclusion across the organization and within the talent acquisition process and throughout the full employee journey. Pamela Hennard has been an integral part of NetApp's success, serving as the Vice President of Global Talent Acquisition. With over 27 years of experience in human resources, Pamela brings a wealth of expertise in developing and leading high-performing teams. During Pam’s tenure at NetApp, her strategic guidance has been instrumental in setting and achieving recruitment and onboarding objectives, while also aligning with diversity, inclusion, and belonging initiatives. Throughout her career, Pamela has been a staunch advocate for diversity and inclusion, working to integrate these principles into human resources proc
ELIQUENT Life Sciences Announces: Rob Wojciechowski Joins Firm31.10.2024 15:39:00 CET | Press release
Wojciechowski to Provide Strategic Leadership in Europe & APAC ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced the appointment of Rob Wojciechowski as Managing Director of the Consulting Practice across Europe and the Asia-Pacific region. This strategic addition to ELIQUENT’s executive team underscores the company’s commitment to continued growth within European and Asian markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241031868837/en/ Rob Wojciechowski (Photo: Business Wire) “Rob’s appointment comes at a pivotal moment for ELIQUENT. His extensive experience in managing consulting practices across diverse markets will be instrumental in expanding our footprint and enhancing our service offerings to meet the unique needs of clients in Europe and the APAC region,” said Tim Dietlin, Chief Executive Officer, ELIQUENT Life Sciences. A seasoned life sciences executive and NED board m
Xsolla and Long Tale Games Launch Charity Campaign With Life Is Feudal to Support Games for Change31.10.2024 14:00:00 CET | Press release
50% Of Proceeds From Subscriptions To Benefit Games For Change Xsolla, a global video game commerce company, has partnered with Long Tale Games to launch a charity campaign. 50% of the proceeds from the 3-month subscription package to Life is Feudal will be donatedto Games For Change. This initiative, running until December 31st, reflects Xsolla’s commitment to leveraging the power of gaming to drive positive change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241031878088/en/ (Graphic: Xsolla) The campaign offers players an exciting adventure in Life is Feudal: MMO and allows them to make a tangible impact. With half of each 3-month subscription supporting educational programs, civic engagement initiatives, and social impact projects, the campaign demonstrates how gaming can foster a better future through the power of play. Players are empowered to engage with a meaningful cause, proving that games are more than just ent
Hassana Investment Company and EIG Sign MoU for Strategic Collaboration on Middle East Infrastructure and Energy Transition Projects31.10.2024 13:00:00 CET | Press release
Collaboration advances shared objectives for investment in the Kingdom of Saudi Arabia and the rest of the region with EIG’s targeted US$1 billion dedicated regional fund Hassana Investment Company (Hassana) and EIG, a leading institutional investor to the global energy and infrastructure sectors, have signed a memorandum of understanding (MoU) to collaborate on infrastructure and energy transition projects in the Middle East through EIG’s targeted US$1 billion dedicated regional fund in which Hassana is considering becoming an anchor investor with an allocation of up to US$250 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241029142798/en/ (Photo: Business Wire) The MoU underscores EIG’s and Hassana’s shared commitment to expand their local and regional infrastructure and energy transition investment portfolios. By fostering participation from international investors and boosting foreign direct investment, this par
Kinaxis Announces Normal Course Issuer Bid31.10.2024 12:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) is pleased to announce that the Toronto Stock Exchange (the “Exchange” or “TSX”) has accepted a notice (the “Notice”) filed by the Company of its intention to make a normal course issuer bid (the “NCIB”). In connection with the NCIB, the Company has entered into an automatic share purchase plan (an “ASPP”) with its designated broker to allow for purchases of its common shares (the “Shares”). The Notice provides that the Company may, during the 12-month period commencing November 6, 2024 and ending November 5, 2025, or on such earlier date as Kinaxis completes its purchases or provides notice of termination, purchase up to 1,404,639 Shares in total, representing approximately 5% of the issued and outstanding Shares as at October 23, 2024. As of the close of business on October 23, 2024, the Company had 28,092,786 Shares issued and outstanding. Except for block purchases permitted under the rules of the TSX, the number of Shares to be
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom